The initial success of the copyright undeniably reshaped the drug landscape, but betting in companies primarily reliant on generic versions presents a uncertain picture. Although early profits were impressive, the expiration of patents and the emergence of discounted alternatives have eroded sales. Thus, a thorough analysis of current financial per